New Biological Discovery Opens Door to Breakthrough Cholesterol Treatment

American researchers have identified a biological mechanism that explains why high-cholesterol diets reduce the liver’s ability to clear LDL cholesterol, according to a study published in the journal Nature. By targeting the enzyme cathepsine A (CTSA), scientists found they could stabilize LDL receptors and significantly lower blood cholesterol concentrations in mice.

Cardiovascular diseases linked to high cholesterol remain the leading cause of death worldwide. While various medications exist, many patients fail to reach target cholesterol levels or experience adverse side effects.

The liver normally regulates blood cholesterol using LDL receptors on the surface of liver cells. These receptors act as nets that capture “bad” LDL cholesterol from the bloodstream and transport it into the cell for processing.

How does a high-cholesterol diet affect the liver?

Existing treatments, such as statins and PCSK9 inhibitors, work by maintaining or increasing the number of LDL receptors. However, diets high in saturated fats are known to decrease these receptors, though the reason remained unclear until now.

The Nature study found that a protein called Ral is activated by long-term high cholesterol intake. This activation leads to a gradual decline in the number of LDL receptors on liver cells, making cholesterol removal less efficient.

Lead researcher Alan Saltiel stated that this discovery explains a significant part of a long-standing puzzle. This process creates a vicious cycle where dietary cholesterol reduces the receptors needed to clear it, allowing more cholesterol to accumulate in the blood.

Did You Know? A CTSA inhibitor was previously developed for heart failure and has already completed a phase 1 study, proving it is safe for human use.

What is the role of the CTSA enzyme?

Researchers determined that the reduction of LDL receptors depends on an enzyme called cathepsine A (CTSA). When scientists blocked CTSA with a specific inhibitor in mice, the LDL receptors stabilized.

This stabilization resulted in a significant drop in LDL cholesterol concentrations in the blood. This makes CTSA a potential new target for future pharmacological interventions.

Expert Insight: Samantha Carter notes that the most significant aspect of this discovery is that the CTSA pathway operates independently of current medications. This independence suggests a possible future where CTSA inhibitors are combined with existing therapies to provide a more robust reduction in cardiovascular risk for non-responsive patients.

What happens next for CTSA inhibitors?

New drugs typically take years to move from discovery to clinical use. This treatment may follow a faster path because the CTSA inhibitor already passed phase 1 safety trials during its previous development for heart failure.

I Lowered My LDL Cholesterol in 48 Hours //Dr Alan Mandel

Researchers could potentially move directly into phase 2 trials to test the drug’s effectiveness in patients with high cholesterol. This would be particularly relevant for individuals who cannot lower their cholesterol sufficiently with current medications.

While further research must confirm if these results translate to humans, the study identifies a previously hidden link in cholesterol regulation. This could lead to a new generation of cholesterol-lowering drugs.

Frequently Asked Questions

What are LDL receptors?
They are structures on the surface of liver cells that function as nets to remove “bad” LDL cholesterol from the bloodstream for processing.

How does the Ral protein affect cholesterol?
When activated by a high-cholesterol diet, the Ral protein causes the number of LDL receptors on liver cells to decrease, which hinders the liver’s ability to clear cholesterol from the blood.

Why might this new treatment be faster to develop than others?
The CTSA inhibitor used in the study was previously tested in a phase 1 study for heart failure, meaning its safety in humans has already been established.

Do you think combining different types of cholesterol medications will become the standard of care for high-risk patients?